Today: 23 January 2026
Subscribe
Browse Category

ASX:EVN News 15 January 2026 - 23 January 2026

Evolution Mining share price jumps 5% as EVN rides gold rally and record cash flow — what to watch next

Evolution Mining share price jumps 5% as EVN rides gold rally and record cash flow — what to watch next

Sydney, Jan 23, 2026, 17:27 AEDT — The market has closed. Evolution Mining Ltd (ASX:EVN) shares climbed 5.3% on Friday, closing at A$14.86. The gold and copper producer saw a late boost following a volatile week for the sector. (Intelligent Investor) Gold-linked stocks gained traction as bullion climbed to new highs, attracting buying in producers closely tied to spot prices.…
23 January 2026
·····
Evolution Mining share price hits record as EVN cuts cost guidance after cash-flow surge

Evolution Mining share price hits record as EVN cuts cost guidance after cash-flow surge

Sydney, Jan 21, 2026, 17:23 AEDT — Market closed. Evolution Mining Ltd jumped roughly 9.5% Wednesday, buoyed by a forecast of record cash flow and falling costs. The Australian gold miner’s shares settled at A$14.79, having hit an intraday high of A$14.855, according to delayed pricing data. (Intelligent Investor) The update came as funds continue pouring into gold, which recently…
21 January 2026
·····
Northern Star shares rise into ASX close as gold cools — what to watch before Jan 22 update

Northern Star shares rise into ASX close as gold cools — what to watch before Jan 22 update

Sydney, Jan 15, 2026, 16:51 AEDT — Market closed. Northern Star Resources Ltd shares climbed 31 Australian cents, or 1.16%, to finish at A$27.04 on Thursday, after swinging between A$26.66 and A$27.43 during the session. (Investing) The stock now heads into a packed schedule of company reports, with Northern Star set to release its December-quarter update next week and the…
15 January 2026
·······

Stock Market Today

  • Treace Medical Concepts (TMCI) Stock Shows 81% Upside Amid Profitability Concerns
    January 23, 2026, 8:12 AM EST. Treace Medical Concepts, Inc. (NASDAQ: TMCI) trades near its 52-week low at $2.69, despite a market cap of $171.4 million and a potential upside of 81% based on average analyst targets of $4.87. The healthcare device maker, known for its Lapiplasty 3D bunion correction system, shows 11.4% revenue growth but faces profitability challenges with a negative forward P/E of -3.96 and EPS of -0.80. Operational efficiency is weak, highlighted by a -51.63% return on equity and negative free cash flow of $9.2 million. Technical indicators reveal bearish momentum amid mixed analyst ratings, underscoring the stock's speculative nature. Investors should weigh growth prospects against financial risks carefully.
Go toTop